Skip to Content

HCA Houston Pearland introduces minimally invasive technique for treatment of enlarged prostate

Aquablation is a safe and effective treatment for patients suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.

March 18, 2024
HCA Houston Healthcare Pearland completed its first elective robotic aquablation procedures at the end of August 2023.

Houston, TX – HCA Houston Healthcare Pearland now offers a new robotic therapy for the treatment of an enlarged prostate or benign prostatic hyperplasia (BPH). The advanced, minimally invasive technique provides long-lasting symptom improvement without compromising sexual function.

BPH, or an enlarged prostate, is a non-cancerous condition where the prostate has grown to be larger than normal. One in two men ages 51 to 60 have BPH, and the incidence increases every decade of life. This common condition is associated with urinating too often, urgently, or at night. If left untreated, BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones and incontinence.

Aquablation therapy is a different type of treatment for BPH. It is an advanced, minimally invasive treatment that uses the power of water delivered with robotic precision to provide long-lasting symptom relief with less irritation, fewer reported side effects and faster recovery than traditional treatment methods.

“We are proud to perform the first robotic Aquablation procedures at HCA Houston Healthcare Pearland,” said David Wagner, CEO of HCA Houston Healthcare Pearland. “Aquablation therapy is the next step to furthering our commitment to robotic surgery and men’s health.”

Ideal candidates include men with moderate to severe BPH symptoms, those who can no longer urinate on their own and have to use a catheter, those with very enlarged prostates, those experiencing other complications of BPH, including kidney failure, infections, bleeding and stones, and those who have not responded to traditional medications.

Published:
March 18, 2024
Location:
HCA Houston Healthcare Pearland